Co-administration Of Albendazole Research Articles

Improvement of Albendazole Bioavailability with Menbutone Administration in Sheep.

Simple SummaryAnthelmintic drugs are among those most widely used in veterinary practice. The development of resistance to these drugs is a widespread problem, especially in small ruminants, and represents a serious threat to animal production. Thus, new possibilities to use the available pharmacological groups in a more efficient way should be explored. The objective of this study was to assess the pharmacokinetic interaction between a benzimidazole (albendazole, ABZ) and a choleretic drug (menbutone, MEN) in sheep, and it may result in greater effectivity of this drug against nematode parasites. Plasma concentrations of ABZSO (ABZ active metabolite) were higher when ABZ was administered with MEN. The proposed interaction is a simple, safe, and inexpensive way of increasing the effectivity of this anthelmintic widely used in livestock.The pharmacokinetic interaction between a benzimidazole (albendazole, ABZ) and a choleretic drug (menbutone, MEN) was evaluated in sheep. The plasma disposition of albendazole sulfoxide (ABZSO, active metabolite) and albendazole sulfone (ABZSO2, inactive metabolite) was investigated following an oral administration of albendazole (ABZ) (5 mg/kg) alone or with menbutone (MEN) (intramuscular, 10 mg/kg). Blood samples were collected over 3 days post-treatment, and drug plasma concentrations were measured by high performance liquid chromatography (HPLC). ABZSO was measured from 0.5 to 48 h, and ABZSO2 from 2 to 60 h. No parent drug was detected at any sampling time. Mean maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC) were 12.8% and 21.5% higher for ABZSO when ABZ and MEN were administered together, which indicates a significant increase in the amount absorbed. The rate of absorption was not modified, with similar values for the time to reach Cmax (tmax) (11.5 h with ABZ + MEN and 10.7 h with ABZ treatment), although no significant differences were observed for these latter pharmacokinetic parameters. Regarding ABZSO2, Cmax, AUC and tmax values were similar after both treatments (ABZ or ABZ + MEN). The results obtained indicate that co-administration of ABZ and MEN may be an interesting and practical option to increase the efficacy of this anthelmintic.

Pharmacokinetic assessment of methimazole-mediated modulation of albendazole biotransformation and efficacy in goats

To assess the hypothesis that hepatic microsomal oxidation inhibitor methimazole (MTH) could increase bioavailability of albendazole (ABZ), a study was undertaken to understand the pharmacokinetics and efficacy of ABZ in goats with and without co-adminstration of ABZ with MTH at 7.5 and 3.0 mg/kg body weight, respectively. Significant increased values (P<0.05) of time to reach concentration maximum (calculated), area under concentration-time curve (0-∞), elimination half-life (t1/2β) and total area under the first movement of plasma drug concentration time curve were observed for ABZ-SO (albendazole sulphoxide) in goats following coadministration of ABZ and MTH. Faecal egg count reduction and lower 95% confidence limit revealed resistance and susceptible for ABZ alone and co-administration of ABZ and MTH, respectively. The dominant nematode exhibiting resistance was Haemonchus spp. ED 50 for egg hatch was 0.196 indicating resistance to benzimidazole. The study suggested that coadministration of ABZ and MTH affects pharmacokinetic disposition of ABZ, which could possibly result in potentiation of anthelmintic activity of ABZ as observed through faecal egg count reduction test.

Pharmacokinetic implications of albendazole biotransformation in goats following interaction with curcuma longa

To test the hypothesis that Curcuma longa could act as hepatic microsomal cytochrome P450 inhibitor resulting in increased bioavailability of albendazole, a study was undertaken to understand the pharmacokinetics and efficacy of albendazole in goats with and without coadministration of albendazole with hydroalcoholic extract of Curcuma longa at 7.5 and 500.0 mg per kg body weight, respectively. The comparative pharmacokinetic values (Mean±S.E.) of albendazole sulphoxide in goats using albendazole and albendazole combination revealed significantly (P<0.05) reduced values of concentration maximum, area under concentration-time curve and total area under the first movement of plasma drug concentration-time curve (P<0.001) in goats receiving albendazole and Curcuma long a. Significantly lower values of under concentration-time curve in goats receiving albendazole in combination with Curcuma longa had resulted in relative bioavailability of 0.57. Estimated drug-parasite contact of albendazole sulphoxide in goats revealed significantly decreased values in goats receiving ABZ combination. Nematode parasites of goats dominated by Haemonchus contortus also exhibited resistant against benzimidazole following administration of albendazole alone and in combination with Curcuma longa. Simultaneous administration of hydroalcoholic extract of Curcuma longa, contrary to the hypothesis, resulted in reduced bioavailability of albendazole.

Enhancement of the Therapeutic Effect of Albendazole on Cystic Echinococcosis using a Herbal Product

ABSTRACTPurpose: Albendazole is the drug of choice for chemotherapy of cystic echinococcosis (CE) but 40% of patients do not respond to it satisfactorily. With regard to the previously reported scolicidal activity of Zataria multiflora, this study was done to evaluate the efficacy of the co-administration of albendazole and Z. multiflora aromatic water (AW) on hydatid cysts in a murine model. Materials and Methods: Laboratory mice were infected with 1,500 viable protoscoleces. After development of hydatid cysts, the infected mice were allocated into four treatment and one control group. The mice of groups 1, 2, 3, and 4 were treated orally with albendazole (100 mg/kg), Z. multiform AW (100 ml/l), albendazole (100 mg/kg) – Z. multiform AW and albendazole ((50 mg/kg) – Z. multiform AW respectively. Two months later, all the mice were euthanized and necropsied and the number, size and weight of hydatid cysts were compared between different groups. Results: The size of the largest cysts, as well as the total weight of cysts, were significantly lower (p < .05) in the mice treated with albendazole (50 mg/kg) – Z. multiflora AW in comparison to those treated with albendazole (100 mg/kg) alone. Conclusions: The results of this study revealed the superiority of co-administration of albendazole and Z. multiflora AW to albendazole alone in the treatment of CE in laboratory mice. Since Z. multiflora AW is a safe and useful drink, it may be used successfully to enhance the therapeutic effect of albendazole in the patients infected with hydatid disease.

Influence of Co-Administration of Parbendazole on The Disposition Kinetics and Efficacy of Albendazole in Goats

A study was undertaken to understand the pharmacokinetics and efficacy of albendazole (ABZ) in goats with and without co-administration of ABZ with parbendazole (PBZ) at 7.5 and 4.5 mg/kg body weight, respectively. Plasma albendazole sulphoxide metabolite (active moiety), reached its maximum concentration of 0.322 and 0.325 μg/ml at 18 h of oral administration of ABZ alone and co-administration of ABZ with PBZ. No significant difference (P>0.05) in the values of other pharmacokinetic parameters could be observed except for elimination half-life, where significantly (P<0.05) increased values were observed in ABZ + PBZ treated goats. The nematodes were found resistant against ABZ alone (ED 50 on egg hatch assay was 0.196 μg thiabendazole/ml) while susceptible against the drug combination. The dominant nematode exhibiting resistance was Haemonchus spp. Almost unaltered or slightly reduced drug-parasite contact was observed in goats receivingABZ and PBZ combination.

A School-Based Cross-Sectional Survey of Adverse Events following Co-Administration of Albendazole and Praziquantel for Preventive Chemotherapy against Urogenital Schistosomiasis and Soil-Transmitted Helminthiasis in Kwale County, Kenya

BackgroundSoil-transmitted helminths and schistosomiasis are mostly prevalent in developing countries due to poor sanitation and lack of adequate clean water. School-age children tend to be the target of chemotherapy-based control programmes because they carry the heaviest worm and egg burdens. The present study examines adverse events (AEs) experienced following co-administration of albendazole and praziquantel to school-age children in a rural area in Kwale County, Kenya.MethodsChildren were treated with single doses of albendazole and praziquantel tablets and then interviewed using a questionnaire for post treatment AEs.ResultsOverall, 752 children, 47.6% boys, participated in the study. Their median (interquartile range) age was 12.0 (10.0–14.0) years. A total of 190 (25.3%) children reportedly experienced at least one AE. In total, 239 cases of AEs were reported with the most frequent being abdominal pains (46.3%), dizziness (33.2%) and nausea (21.1%). Majority of the reported AEs (80.8%) resolved themselves while 12.1% and 6.3% were countered by, respectively, self-medication and visiting a nearby health facility. More girls (60.5%) than boys (39.5%) reported AEs (P = 0.027).ConclusionsThe AEs were mild and transient, and were no worse than those expected following monotherapy. The current study adds to the evidence base that dual administration of albendazole and praziquantel in school-based mass drug administration is safe with only mild adverse events noted.

Evaluation of the interaction between ivermectin and albendazole following their combined use in lambs

Mixtures of drugs from different chemical families have been proposed as a valid strategy to delay the development of anthelmintic resistance. The current work summarizes the outcome of the evaluation of the plasma disposition kinetics of albendazole (ABZ) and ivermectin (IVM) administered either alone or co-administered to lambs infected with gastrointestinal (GI) nematodes resistant to both anthelmintic molecules. Thirty six (36) Corriedale lambs naturally infected with multiple resistant GI nematodes were allocated into six treatment groups: (a) ABZ intravenous (ABZ(IV)); (b) IVM(IV); (c) ABZ(IV) + IVM(IV); (d) ABZ intraruminal (IR); (e) IVM subcutaneous (SC) and (f) ABZ(IR) + IVM(SC). Plasma samples were collected over 15 days post-treatment and analysed by HPLC. The estimated pharmacokinetic (PK) parameters were statistically compared using parametric and non-parametric statistical tests. The presence of IVM did not affect the plasma disposition kinetics of ABZ and its metabolites after the i.v. administration. However, the ABZ sulphoxide (ABZSO) area under the concentration vs. time curve (AUC) was significantly lower (P < 0.01) after the intraruminal (i.r.) administration of ABZ alone compared to that obtained for the combined treatment with IVM [subcutaneous (s.c.) injection]. The IVM plasma AUC obtained after its i.v. co-administration with ABZ was 88% higher (P < 0.05) compared to the treatment with IVM alone. Any marked difference on IVM PK parameters was observed between the treatments ABZ + IVM and IVM alone injected subcutaneously. The data obtained here indicate that the co-administration of ABZ and IVM does not induce an adverse kinetic interaction. This type of pharmacology-based evaluation of drug interactions is becoming highly relevant as drug combinations are now widely used as an alternative to control resistant helminth parasites in livestock.

Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co-administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital-based study

BackgroundThe tolerability and efficacy of single dose albendazole (400 mg), diethylcarbamazine citrate (DEC) (6 mg/kg bodyweight) or co-administration of albendazole (400 mg) + DEC (6 mg/kg bodyweight) was studied in 54 asymptomatic Wuchereria bancrofti microfilaraemic volunteers in a double blind hospital-based clinical study.ResultsThere was no significant difference in the overall incidence of adverse reactions between the three drug groups [42.1% (albendazole), 52.9% (DEC) and 61.1% (albendazole + DEC); P > 0.05]. The mean score of adverse reaction intensity did not differ significantly between the DEC and albendazole + DEC groups. However, the values in these two groups were significantly higher compared to that of albendazole alone [1.8 ± 3.0 (albendazole) vs. 5.6 ± 7.1 (DEC), 6.7 ± 6.6 (albendazole + DEC); P < 0.05]. By day 360 post-therapy there was no significant difference between the three drug groups in relation to the clearance of microfilaria [26.3% (albendazole), 17.6% (DEC), 27.8% (albendazole + DEC)], reduction in geometric mean parasite density [94.7% (albendazole), 89.5% (DEC), 95.4% (albendazole + DEC)] or reduction in filarial antigenaemia [83% (albendazole), 87% (DEC), 75% (albendazole + DEC)]. Furthermore, there was a significant decrease in mean geometric parasite density (P < 0.05) as well as antigenaemia optical density values (P < 0.01) between pre-therapy levels and day 360 post-therapy in all three groups.ConclusionsThis study has shown that single dose albendazole (400 mg) has similar efficacy in the clearance of microfilaria as that of DEC or the co-administration of the two drugs. The results strengthen the rationale of using albendazole for mass annual single dose administration for the control of transmission of lymphatic filariasis.